AR065798A1 - Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina - Google Patents

Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina

Info

Publication number
AR065798A1
AR065798A1 ARP080101146A ARP080101146A AR065798A1 AR 065798 A1 AR065798 A1 AR 065798A1 AR P080101146 A ARP080101146 A AR P080101146A AR P080101146 A ARP080101146 A AR P080101146A AR 065798 A1 AR065798 A1 AR 065798A1
Authority
AR
Argentina
Prior art keywords
piperidine
phenyl
methylphenylsulphanil
therapeutic uses
treatment
Prior art date
Application number
ARP080101146A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR065798A1 publication Critical patent/AR065798A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Reivindicacion 11: 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sales de adicion de ácidos de la misma para usar en el tratamiento del ADHD, melancolía, depresion resistente al tratamiento o síntomas residuales en la depresion. Reivindicacion12: 13. El compuesto de acuerdo con la reivindicacion 11, cuyo compuesto e la sal de adicion de HBr.
ARP080101146A 2007-03-20 2008-03-19 Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina AR065798A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
AR065798A1 true AR065798A1 (es) 2009-07-01

Family

ID=39575680

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101146A AR065798A1 (es) 2007-03-20 2008-03-19 Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina

Country Status (28)

Country Link
US (2) US20100144788A1 (es)
EP (2) EP2139479B1 (es)
JP (1) JP5388867B2 (es)
KR (1) KR20090125775A (es)
CN (2) CN101674830B (es)
AR (1) AR065798A1 (es)
AU (1) AU2008228639B2 (es)
BR (1) BRPI0808831A2 (es)
CA (1) CA2684556C (es)
CL (1) CL2008000796A1 (es)
CO (1) CO6220957A2 (es)
CY (2) CY1113965T1 (es)
DK (2) DK2139479T3 (es)
EA (1) EA017407B1 (es)
ES (2) ES2399305T3 (es)
HK (1) HK1142007A1 (es)
HR (1) HRP20130049T1 (es)
IL (1) IL200954A (es)
MX (1) MX2009009934A (es)
MY (1) MY163537A (es)
NZ (1) NZ579723A (es)
PL (2) PL2139479T3 (es)
PT (2) PT2139479E (es)
RS (2) RS52676B (es)
SI (1) SI2139479T1 (es)
TW (1) TWI432194B (es)
UA (2) UA97660C2 (es)
WO (1) WO2008113360A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007260356B2 (en) * 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
JP5764327B2 (ja) * 2007-06-15 2015-08-19 ハー・ルンドベック・アクチエゼルスカベット 過敏性腸症候群（ｉｂｓ）を処置するための４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
KR20130060220A (ko) * 2010-04-30 2013-06-07 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제
US8745134B1 (en) 2011-03-04 2014-06-03 Zynga Inc. Cross social network data aggregation
US8332488B1 (en) 2011-03-04 2012-12-11 Zynga Inc. Multi-level cache with synch
US8347322B1 (en) 2011-03-31 2013-01-01 Zynga Inc. Social network application programming interface
US10135776B1 (en) 2011-03-31 2018-11-20 Zynga Inc. Cross platform social networking messaging system
US8522137B1 (en) 2011-06-30 2013-08-27 Zynga Inc. Systems, methods, and machine readable media for social network application development using a custom markup language
CN109310691A (zh) 2016-07-01 2019-02-05 H.隆德贝克有限公司 用于快速开始抗抑郁作用的给药方案

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010043730A (ko) * 1998-05-22 2001-05-25 피터 지. 스트링거 치료 불응성 우울증의 치료를 위한 조합 치료법
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ATE392896T1 (de) * 2003-04-04 2008-05-15 Lundbeck & Co As H 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6- tetrahydropyridin-derivate als serotonin- wiederaufnahme-hemmer
PT1626720E (pt) * 2003-04-04 2008-11-10 Lundbeck & Co As H Derivados de 4-(2-fenilsulfanil-fenil)-piperidina como inibidores da recaptação da serotonina
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
DE102006028034A1 (de) * 2006-06-14 2007-12-20 Leifheit Ag Bürste und Kehrgerät mit Bürste
AU2007260356B2 (en) * 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter

Also Published As

Publication number Publication date
HRP20130049T1 (hr) 2013-02-28
CY1114774T1 (el) 2016-12-14
CY1113965T1 (el) 2016-07-27
EP2167085B1 (en) 2013-12-25
UA99611C2 (ru) 2012-09-10
BRPI0808831A2 (pt) 2014-08-26
HK1142007A1 (en) 2010-11-26
TWI432194B (zh) 2014-04-01
AU2008228639A1 (en) 2008-09-25
WO2008113360A3 (en) 2008-11-13
UA97660C2 (ru) 2012-03-12
RS52676B (en) 2013-06-28
CL2008000796A1 (es) 2008-09-26
SI2139479T1 (sl) 2013-04-30
EP2167085A1 (en) 2010-03-31
JP5388867B2 (ja) 2014-01-15
DK2139479T3 (da) 2013-02-11
CN101646438A (zh) 2010-02-10
US20100144788A1 (en) 2010-06-10
US20100137366A1 (en) 2010-06-03
MX2009009934A (es) 2009-09-24
EP2139479B1 (en) 2012-12-12
KR20090125775A (ko) 2009-12-07
IL200954A (en) 2014-12-31
US8507526B2 (en) 2013-08-13
IL200954A0 (en) 2010-05-17
EA017407B1 (ru) 2012-12-28
CN101674830A (zh) 2010-03-17
MY163537A (en) 2017-09-15
AU2008228639B2 (en) 2012-12-13
RS53138B (en) 2014-06-30
DK2167085T3 (da) 2014-02-03
PT2139479E (pt) 2013-02-20
PL2139479T3 (pl) 2013-05-31
CO6220957A2 (es) 2010-11-19
ES2445400T3 (es) 2014-03-03
JP2010521502A (ja) 2010-06-24
CN101646438B (zh) 2012-04-11
ES2399305T3 (es) 2013-03-27
TW200848032A (en) 2008-12-16
PL2167085T3 (pl) 2014-08-29
CA2684556C (en) 2013-01-08
EA200970871A1 (ru) 2010-04-30
CA2684556A1 (en) 2008-09-25
CN101674830B (zh) 2012-05-09
EP2139479A2 (en) 2010-01-06
WO2008113360A2 (en) 2008-09-25
PT2167085E (pt) 2014-02-17
NZ579723A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
AR065798A1 (es) Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina
LTPA2020534I1 (lt) 1-((5-Heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamido dariniai, kaip fosfatidilinozitolio 3-kinazės (PI3K) inhibitoriai, naudingi proliferacinių ligų gydyme
AR065797A1 (es) Usos y derivados de 1-(2- (2,4- dimetilfenilsulfanil) fenil) piperazina
CR20110343A (es) Inhibidores de proteína cinasa
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
CL2013002737A1 (es) Acido 4-((4-((((1r, 2s)-2-fenilciclopropil)amino)metil)piperidin-1-il)metil)benzoico con actividad inhibidora de desmetilasa 1 especifica de lisina (lsd1); composicion farmaceutica que lo comprende, utiles en el tratamiento del cancer.
EA201100302A1 (ru) Лечение диабета у пациентов, для которых лечение метформином является неприемлемым
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
CO6460766A2 (es) Compuestos de haloalquil heteroaril benzamida
PA8850801A1 (es) Compuestos útiles para inhibir chk1
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
UY30476A1 (es) Noveles compuestos derivados n-sustituidos de la 3-oxoisoindolin-1-carboxamida, sus sales aceptables, composiciones farmaccuticas y aplicaciones.
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
CO6361993A2 (es) Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
UY30029A1 (es) Derivados de piperidina, sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
BR112014009165A2 (pt) sal e uso médico
UY30284A1 (es) Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca
ATE481395T1 (de) Cyclohexylderivate

Legal Events

Date Code Title Description
FB Suspension of granting procedure